NCT04987879Completed
NASH AMPK Exercise Dosing (AMPED) Trial
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD. While physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 13 Jul 2021
- Start date
- 30 Aug 2022
- Primary completion date
- 10 Feb 2026
- Lead sponsor
- Milton S. Hershey Medical Center
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT04987879
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 30 Aug 2022 to the primary completion date, 10 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Uncontrolled diabetes (changes in drug dosing over previous three months or A1c \>9%)
Other illness
- Active cardiac symptoms
- Cancer that is active
- Other liver disease
Other
- Body mass index (BMI) \>45kg/m2
- Inability to walk \>2 blocks
- Institutionalized/prisoner
- Pregnancy
- Secondary hepatic steatosis
- Severe comorbidities
- AUDIT-C questionnaire identified significant alcohol use
- Substance abuse/active smoking
- GAQ response indicates exercise may be unsafe.
Who the study is looking for
- Age 18-69 years
- Sedentary \[\<90 min/wk of exercise identified by the Get Active Questionnaire (GAQ)
- BMI \>25kg/m2
- Liver biopsy within six months prior to enrollment showing:
- NASH defined by NASH Clinical Research Network (CRN) histology scoring system (NAS) \>4 and MRI-PDFF \>5% and;
- Liver fibrosis stage 1-3
Age in the registry: 18 years to 69 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Penn State Hershey Medical Center Coordinator of this site? Confirm its status | Hershey | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.